Oragenics Inc. (OGEN) has completed a crucial study demonstrating the effectiveness of its new concussion drug, ONP-002, in reaching the brain via nasal delivery. This promising result puts the company closer to conducting human trials, offering potential hope for a much-needed treatment for concussions.
Oragenics Inc (OGEN) shares dropped sharply after announcing a public offering of 8.1 million shares at $0.55 per share. The offering is expected to close around September 5th and raise approximately $4.45 million. The funds will be used for developing the company’s ONP-002 product and general corporate purposes. This news comes as OGEN stock has already experienced significant losses year-to-date.
